Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13-valent pneumococcal conjugate vaccine coadministration with DTaP in 3‑month-old infants
CTR20220707Phase 4Completed
- Sponsor
- Yuxi Watson Biotechnology
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of 13-valent pneumococcal polysaccharide conjugate vaccine in pneumococcal disease, Pneumococcal pneumonia (PP), pneumococcal meningitis and 1 more (2 arms), sponsored by Yuxi Watson Biotechnology. Started Mar 2022; status: completed.
02
Drugs
13-valent pneumococcal polysaccharide conjugate vaccine
03
Conditions
pneumococcal diseasePneumococcal pneumonia (PP)pneumococcal meningitispneumococcal bacteremia
Beyond the preview
Go deeper on CTR20220707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220707.